| Not Yet Recruiting | Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema Immunogenicity, Anti-drug Antibodies (ADAs) | Phase 1 | 2026-03-01 |
| Not Yet Recruiting | Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Dry Eye Disease, Dry Eye Sensation, Ocular Surface Disease | Phase 1 | 2026-01-30 |
| Not Yet Recruiting | Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes | Phase 1 | 2025-12-30 |
| Recruiting | PRO-232 in Patients Subjected to Cataract Surgery Cataract Extraction | Phase 3 | 2025-10-27 |
| Completed | Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes Ophthalmological Agent Toxicity | Phase 4 | 2025-05-23 |
| Recruiting | Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Myopia, Myopia, Progressive | Phase 3 | 2025-03-15 |
| Withdrawn | Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensatio Eye Strain, Eye Strain of Both Eyes | Phase 4 | 2025-02-11 |
| Completed | Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Of Dry Eye Disease, Ocular Surface Disease | Phase 1 | 2024-05-16 |
| Completed | Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. Healthy | Phase 1 | 2024-02-08 |
| Completed | Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Sub Ophthalmological Agent Toxicity, Bacterial Conjunctivitis | Phase 1 | 2024-01-30 |
| Completed | Safety and Tolerability of PRO-185 Hyperemia Eye | Phase 1 | 2023-02-04 |
| Withdrawn | Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution Myopia | Phase 1 | 2023-02-01 |
| Completed | Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratecto Photorefractive Keratectomy, Corneal De-epithelialization | Phase 4 | 2022-09-03 |
| Completed | Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201 Myopia | Phase 1 | 2022-08-20 |
| Completed | Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatmen Dry Eye | Phase 2 | 2022-01-03 |
| Completed | Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® Dry Eye | Phase 4 | 2021-12-09 |
| Terminated | Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® fo Glaucoma, Open-Angle, Ocular Hypertension | Phase 4 | 2021-10-19 |
| Completed | Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat. Age-related Cataract, Phacoemulsification | N/A | 2021-09-07 |
| Completed | Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema Diabetic Macular Edema | Phase 3 | 2021-05-24 |
| Completed | Clinical Trial to Compare the Safety and Efficacy of Nanodrop® Dry Eye | Phase 1 / Phase 2 | 2020-12-01 |
| Completed | Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Safety, Tolerability, Ocular Surface | Phase 1 | 2020-09-24 |
| Completed | Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution Dry Eye | Phase 1 | 2019-09-09 |
| Completed | Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® Glaucoma | Phase 1 | 2019-05-02 |
| Completed | Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® Glaucoma | Phase 1 | 2019-04-24 |
| Completed | Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsif Cataract | Phase 3 | 2018-10-04 |
| Terminated | Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Conjunctivitis, Bacterial | Phase 3 | 2018-10-01 |
| Completed | Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Dry Eye Syndromes | Phase 1 | 2018-08-20 |
| Completed | Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects Conjunctivitis, Conjunctivitis, Bacterial | Phase 1 | 2018-01-25 |
| Completed | Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pteryg Pterygium, Ocular Pain, Ocular Inflammation | Phase 4 | 2017-12-13 |
| Terminated | PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) Primary Open-angle Glaucoma | Phase 3 | 2017-11-06 |
| Completed | Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects. Dry Eye, Dry Eye Syndrome of Unspecified Lacrimal Gland | Phase 1 | 2017-10-04 |
| Completed | Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Su Dry Eye Syndromes, Lubricant Allergy, Tear Disorder | Phase 1 | 2017-07-17 |
| Completed | Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087 Dry Eye Syndrome | Phase 4 | 2016-10-13 |
| Completed | Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFOR Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | 2016-04-01 |
| Terminated | Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | 2015-09-01 |
| Completed | Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazu Bacterial Conjunctivitis | Phase 2 | 2015-03-01 |
| Withdrawn | Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjuncti Allergic Conjunctivitis | Phase 3 | 2014-11-01 |
| Completed | Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification Cataract, Phacoemulsification Cataract Surgery | Phase 2 | 2013-12-01 |
| Withdrawn | Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. Conjunctivitis, Bacterial | Phase 1 | 2013-11-01 |
| Completed | Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye Dry Eye | Phase 3 | 2013-11-01 |
| Completed | Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers. Healthy | Phase 1 | 2013-09-01 |
| Completed | Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye S Dry Eye Syndrome | Phase 2 | 2011-10-01 |
| Completed | Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers. Inflammation, Cataract | Phase 1 | 2011-09-01 |
| Withdrawn | Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis Ocular Itching, Ocular Allergy, Seasonal Allergic Conjunctivitis | Phase 2 | 2011-03-01 |
| Completed | Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | 2006-02-01 |